Biomarkers in psychiatry: Potentials, pitfalls, and pragmatics

Primary Psychiatry

Volumn 15, Issue 3, 2008, Pages 54-59

  Cook, Ian A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CHAPERONE; GLUTAMATE RECEPTOR; NORTRIPTYLINE; PAROXETINE; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST;

CLINICAL TRIAL; DISEASE COURSE; ELECTROENCEPHALOGRAPHY; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; MOOD DISORDER; PROGNOSIS; REVIEW; SLEEP DEPRIVATION; TREATMENT RESPONSE;

EID: 61849156256     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Bast RC Jr, Lilja H, Urban N, et al. Translational crossroads for biomarkers. Clin Cancer Res. 2005;11(17):6103-6108.
2. Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer. 2007;6:25.
3. Rhodes DR, Chinnaiyan AM. Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. Ann N Y Acad Sci. 2004;1020:32-40.
4. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007;8(9):813-821.
5. Manenti ER, Bodanese LC, Camey SA, Polanczyk CA. Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes. Clin Cardiol. 2006;29(9):405-410.
6. Wu AH, Jaffe AS, Apple FS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. Oct 22, 2007 [Epub ahead of print].
7. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol. 2007;16(1):14-21.
8. Reddy UM. Prediction and prevention of recurrent stillbirth. Obstet Gynecol. 2007;110(5):1151-1164.
9. Landewé R. Predictive markers in rapidly progressing rheumatoid arthritis. J Rheumatol Suppl. 2007;80:8-15.
10. Ahmed S, Mozley PD, Potter WZ. Biomarkers in psychotropic drug development. Am J Geriatr Psychiatry. 2002;10(6):678-686.
11. Vergare MJ, Binder RL, Cook IA, et al. Psychiatric Evaluation of Adults. 2nd ed. Arlington, VA: American Psychiatric Association; 2006.
12. Berger PA, Faull KF, Kilkowski J, et al. CSF monoamine metabolites in depression and schizophrenia. Am J Psychiatry. 1980;137(2):174-180.
13. Garvey M, Hollon SD, DeRubeis RJ, Evans MD, Tuason VB. Does 24-h urinary MHPG predict treatment response to antidepressants? I. A review. J Affect Disord. 1990;20(3):173-179.
14. Carroll BJ, Cassidy F, Naftolowitz D, et al. Pathophysiology of hypercortisolism in depression. Acta Psychiatr Scand Suppl. 2007;(433):90-103.
15. Carroll BJ. Dexamethasone suppression test: a review of contemporary confusion. J Clin Psychiatry. 1985;46(2 Pt 2):13-24.
16. Rush AJ, Weissenburger JE. Melancholic symptom features and DSM-IV. Am J Psychiatry. 1994;151(4):489-498.
17. Howland RH, Thase ME. Biological studies of dysthymia. Biol Psychiatry. 1991;30(3):283-304.
18. Lee KH, Williams LM. Eye movement dysfunction as a biological marker of risk for schizophrenia. Aust N Z J Psychiatry. 2000;34(suppl):S91-S100.
19. Copolov D, Crook J. Biological markers and schizophrenia. Aust N Z J Psychiatry. 2000;34(suppl):S108-S112.
20. Crowell SE, Beauchaine TP, Gatzke-Kopp L, et al. J. Autonomic correlates of attention-deficit/hyperactivity disorder and oppositional defiant disorder in preschool children. J Abnorm Psychol. 2006;115(1):174-178.
21. Nichols L, Pike VW, Cai L, Innis RB. Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease? Biol Psychiatry. 2006;59(10):940-947.
22. Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 2008;7(2):161-172.
23. Kumar A, Ajilore O. Magnetic resonance imaging and late-life depression: potential biomarkers in the era of personalized medicine. Am J Psychiatry. 2008;165(2):166-168.
24. Olvera RL, Caetano SC, Fonseca M, et al. Low levels of N-acetyl aspartate in the left dorsolateral prefrontal cortex of pediatric bipolar patients. J Child Adolesc Psychopharmacol. 2007;17(4):461-473.
25. Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343(7):450-456.
26. Kraemer HC, Schultz SK, Arndt S. Biomarkers in psychiatry: methodological issues. Am J Geriatr Psychiatry. 2002;10(6):653-659.
27. Smith GS, Gunning-Dixon FM, Lotrich FE, Taylor WD, Evans JD. Translational research in late-life mood disorders: implications for future intervention and prevention research. Neuropsychopharmacology. 2007;32(9):1857-1875.
28. Baldessarini RJ, Conwell Y, Fawcett JA, et al. Practice Guideline for the Assessment and Treatment of Patients with Suicidal Behaviors. Arlington, VA: American Psychiatric Association; 2003.
29. Pompili M, Ehrlich S, De Pisa E, et al. White matter hyperintensities and their associations with suicidality in patients with major affective disorders. Eur Arch Psychiatry Clin Neurosci. 2007;257(8):494-499.
30. Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007;164(10):1530-1538.
31. Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007;64(6):689-697.
32. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152(10):1500-1503.
33. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
34. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology. 2007;32(12):2479-2489.
35. Sussman N. Translating science into service: lessons learned from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Prim Care Companion J Clin Psychiatry. 2007;9(5):331-337.
36. Rasmussen-Torvik LJ, McAlpine DD. Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils. Depress Anxiety. 2007;24(5):350-357.
37. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804-814.
38. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007;164(8):1181-1188.
39. Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response-an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) cohort. Biol Psychiatry. Jan 10, 2008 [Epub ahead of print].
40. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9(12):819-825.
41. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007;12(8):707-747.
42. Xu K, Ernst M, Goldman D. Imaging genomics applied to anxiety, stress response, and resiliency. Neuroinformatics. 2006;4(1):51-64.
43. Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci. 2006;7(7):583-590.
44. Leuchter AF, Uijtdehaage SH, Cook IA, O'Hara R, Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res. 1999;90(2):125-140
45. Cook IA, Leuchter AF. Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry. 2001;6(2):113-120
46. Cook IA, Leuchter AF, Morgan M, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002;27(1):120-131.
47. Cook IA, Leuchter AF, Morgan ML, Stubbeman W, Siegman B, Abrams M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J Psychiatr Res. 2005;39(5):461-466.
48. Leuchter AF, Cook IA, Uijtdehaage SH, et al. Brain structure and function and the outcomes of treatment for depression. J Clin Psychiatry. 1997;58(suppl 16):22-31.
49. Hunter AM, Cook IA, Leuchter AF. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. Psychiatr Clin North Am. 2007;30(1):105-124.
50. Bareš M, Brunovsky M, Kopecek M, et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. J Psychiatr Res. 2007;41(3-4):319-325.
51. Leuchter AF, Cook IA, Marangell LB, et al. Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD): Predictors of Clinical Treatment Response. Poster presented at: the Annual Meeting of the Society of Biological Psychiatry; San Diego, CA; May 17, 2007.
52. Leuchter AF, Cook IA, Gilmer W, et al. EEG-guided Antidepressant Selection May Improve Response Rates: Insights from the BRITE-MD Trial. Poster presented: the 47th Annual Meeting of the New Clinical Drug Evaluation Unit; Boca Raton, FL; June 11-14, 2007.
53. Leuchter AF, Cook IA, Marangell LB, et al. Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD): Predictors of clinical response and remission to escitalopram. Poster presented at: the Annual Meeting of the American College of Neuropsychopharmacology; Boca Raton, FL; December 8-12, 2007.
54. Hegerl U, Juckel G. Identifying psychiatric patients with serotonergic dysfunctions by event-related potentials. World J Biol Psychiatry. 2000;1(2):112-118.
55. Nathan PJ, Segrave R, Phan KL, O'Neill B, Croft RJ. Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function. Hum Psychopharmacol. 2006;21(1):47-52.
56. Pogarell O, Juckel G, Norra C, et al. Prediction of clinical response to antidepressants in patients with depression: neurophysiology in clinical practice. Clin EEG Neurosci. 2007;38(2):74-77.
57. Norra C, Becker S, Bröcheler A, Kawohl W, Kunert HJ, Buchner H. Loudness dependence of evoked dipole source activity during acute serotonin challenge in females. Hum Psychopharmacol. 2008;23(1):31-42.
58. Guille V, Croft RJ, O'Neill BV, Illic S, Phan KL, Nathan PJ. An examination of acute changes in serotonergic neurotransmission using the loudness dependence measure of auditory cortex evoked activity: effects of citalopram, escitalopram and sertraline. Hum Psychopharmacol. Jan 15, 2008; [Epub ahead of print].
59. Gallinat J, Bottlender R, Juckel G, et al. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl). 2000;148(4):404-411.
60. Mulert C, Juckel G, Augustin H, Hegerl U. Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression. Clin Neurophysiol. 2002;113(10):1566-1572.
61. Lee TW, Yu YW, Chen TJ, et al. Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression. J Psychiatry Neurosci. 2005;30(3):202-205.
62. Linka T, Müller BW, Bender S, Sartory G, Gastpar M. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. Pharmacopsychiatry. 2005;38(3):139-143.
63. Mulert C, Juckel G, Brunnmeier M, et al. Prediction of treatment response in major depression: integration of concepts. J Affect Disord. 2007;98(3):215-225.
64. Wu JC, Gillin JC, Buchsbaum MS, Hershey T, Johnson JC, Bunney WE Jr. Effect of sleep deprivation on brain metabolism of depressed patients. Am J Psychiatry. 1992;149(4):538-543.
65. Wu J, Buchsbaum MS, Gillin JC, et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry. 1999;156(8):1149-1158. Erratum in: Am J Psychiatry. 1999;156(10):1666.
66. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8(4):1057-1061.
67. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry. 2001;158(3):405-415.
68. Saxena S, Brody AL, Ho ML, et al. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry. 2003;160(3):522-532.
69. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728-1733.
70. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chemistry. 1993;39(8):561-577.
71. Altman DG, Bland JM. Diagnostic tests 1: sensitivity and specificity. BMJ. 1994;308(6943):1552.
72. Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ. 1994;309(6947):102.